Skip to main content
PMC home page
PLOS ONE logoLink to PLOS ONE
. 2013 Dec 31;8(12):e84116. doi: 10.1371/journal.pone.0084116

Bone Marrow-Derived Mesenchymal Stem Cells Maintain the Resting Phenotype of Microglia and Inhibit Microglial Activation

Ke Yan 1, Run Zhang 1, Chengmei Sun 1, Lei Chen 1,2, Peng Li 1,3, Yi Liu 1, Lingmei Peng 1,4, Haitao Sun 1, Kun Qin 1,5, Fanfan Chen 1,3, Weiyi Huang 1, Yuxin Chen 1, Bingke Lv 1, Mouxuan Du 1, Yuxi Zou 1, Yingqian Cai 1, Lingsha Qin 1, Yanping Tang 1, Xiaodan Jiang 1,*
Editor: Jialin Charles Zheng6
PMCID: PMC3877190  PMID: 24391898

Abstract

Many studies have shown that microglia in the activated state may be neurotoxic. It has been proven that uncontrolled or over-activated microglia play an important role in many neurodegenerative disorders. Bone marrow-derived mesenchymal stem cells (BMSCs) have been shown in many animal models to have a therapeutic effect on neural damage. Such a therapeutic effect is attributed to the fact that BMSCs have the ability to differentiate into neurons and to produce trophic factors, but there is little information available in the literature concerning whether BMSCs play a therapeutic role by affecting microglial activity. In this study, we triggered an inflammatory response situation in vitro by stimulating microglia with the bacterial endotoxin lipopolysaccharide (LPS), and then culturing these microglia with BMSC-conditioned medium (BMSC-CM). We found that BMSC-CM significantly inhibited proliferation and secretion of pro-inflammatory factors by activated microglia. Furthermore, we found that the phagocytic capacity of microglia was also inhibited by BMSC-CM. Finally, we investigated whether the induction of apoptosis and the production of nitric oxide (NO) were involved in the inhibition of microglial activation. We found that BMSC-CM significantly induced apoptosis of microglia, while no apoptosis was apparent in the LPS-stimulated microglia. Our study also provides evidence that NO participates in the inhibitory effect of BMSCs. Our experimental results provide evidence that BMSCs have the ability to maintain the resting phenotype of microglia or to control microglial activation through their production of several factors, indicating that BMSCs could be a promising therapeutic tool for treatment of diseases associated with microglial activation.

Introduction

As the resident immune cells of the central nervous system (CNS), microglia primarily participate in tissue defense and protection of the brain. They are deeply involved in lesions, stroke, brain tumors, and neurodegenerative diseases [1], and play an important role in antigen-presenting, phagocytosis of pathogens, cytokine production and nerve repair. In the normal brain, microglia are in a “resting” state, expressing low levels of most immune receptors such as pattern recognition receptors, chemokine receptors, and major histocompatibility complex molecules, which are all essential to the initiation and propagation of immune responses [2]. Numerous studies have provided evidence that microglia can be mobilized in response to many injuries and diseases of the CNS [3]–[5]. Threats to CNS homeostasis can transform microglia from a resting state to an activated state and cause them to undergo morphological and functional transformations. Activated microglia release more pro-inflammatory factors such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β and nitric oxide (NO), which are neurotoxic [6], [7]. Furthermore, activated microglia show enhanced phagocytic activity, in which state they can phagocytose apoptotic neural cells, and even normal neurons [8]. Experiments have also shown that microglial activation is amplified and prolonged in the aged brain compared to the adult brain [9]. All this evidence demonstrates that microglia can have deleterious effects under some special circumstances, and that uncontrolled inflammatory responses caused by activated microglia contribute to the severity of traumatic brain injury (TBI) and many neurodegenerative diseases [6], [10]. There is also some evidence showing that blockade of microglial activation by anti-inflammatory agents such as minocycline attenuates pathology in Parkinson's disease [11].

Recently, mesenchymal stem cells (MSCs) have been considered as a promising donor source for tissue repair and regeneration [12]–[14]. These cells can be isolated from many adult tissues, including bone marrow, adipose tissue, placenta, and amniotic fluid [15]. It has been demonstrated that MSCs are multipotent and have the ability to differentiate into a variety of mesodermal lineages, including adipocytes, osteocytes and chondrocytes, as well as other embryonic lineages [16]. Because of their lack of immunogenicity, MSCs are able to escape the recognition of alloreactive T cells and natural killer cells. The therapeutic effect of MSCs has been proven in many studies. For example, MSCs have been used successfully in humans to control severe acute graft-versus-host disease (GVHD) of the gut and liver [12]. MSCs transplanted into the heart have the ability to promote cardiac tissue regeneration after myocardial infarction [13]. In vitro, MSCs can inhibit pancreatic islet antigen-specific T cell activation, providing evidence that MSCs may be beneficial for islet engraftment in type 1 diabetes [14]. All of these studies indicate that MSCs may be a promising tool for use in clinical therapy.

There is increasing evidence in animal models of traumatic brain injury (TBI) and spinal cord injury (SCI) that MSCs play an important role in the repair of central nervous system damage [17], [18]. The mechanism responsible for this phenomenon may be attributed to their transdifferentiation, enabling them to replace damaged neural cells and produce growth factors [19]. Many experiments have shown that MSCs transplanted into the brain or spinal cord can directionally migrate into the damaged tissue, and there differentiate into neuron-like cells expressing NeuN and into astrocytes expressing GFAP [20]. Furthermore, MSCs can produce an array of growth factors such as vascular endothelial growth factor (VEGF), brain-derived neurotrophic factor (BDNF), glia-derived neurotrophic factor (GDNF) and hepatocyte growth factor (HGF), all of which are crucial components for neural damage repair [21]–[24]. In spite of this, few studies have focused on whether MSCs exert their therapeutic role by affecting the activity of microglial cells. In this study, we used rat bone marrow-derived mesenchymal stem cells (BMSCs) in combination with allogeneic microglia, to investigate whether BMSCs have any influence on microglial activity. Additionally, we analyzed the possible mechanisms responsible for these effects.

Methods

Ethics statements

Sprague-Dawley (SD) rats were supplied by the Animal Experiment Center of Southern Medical University (Guangzhou, China). Animals were housed under a 12-h light/dark cycle, with food and water freely available. All of the experimental procedures were approved by the Southern Medical University Ethics Committee. All surgery was performed under sodium pentobarbital anesthesia, and efforts were made to minimize numbers and suffering of animals used.

Generation of rat bone marrow-derived MSCs and collection of conditioned medium

BMSCs were obtained from adult male Sprague-Dawley rats weighing 80–120 g. Briefly, The femurs and tibias of the rats were dissected out under aseptic conditions, and then both ends of the bones were cut off. The cells were rinsed from the marrow cavity of the femurs and tibias with 5 mL of Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F-12) using a 25-guage needle. The cells obtained were suspended in D-MEM/F-12 supplemented with 10% fetal bovine serum (FBS) and plated into 25cm2 culture flasks. After incubating for 3 days at 37°C in a 5% CO2 humidified atmosphere, the medium was changed in order to remove non-adherent cells. The remaining adherent cells (primary BMSCs) were passaged every 2 days. Cells from 3 to 5 generations were used in our experiments. The expression of the typical markers CD44 and CD90, and the absence of the hematopoietic markers CD34 and CD45, were assessed by cytofluorometric analysis.

BMSCs (5×105 in 5 mL) were plated into 25 cm2 culture flasks in Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F-12) containing 10% FBS. After 24 hours, the medium was replaced with 5 mL DMEM/F-12 without FBS and the cells were incubated for another 24 hours, at the end of which time, the medium was collected and centrifuged at 300× g for 3 minutes to remove debris before use. The medium thus obtained was defined as BMSC-conditioned medium (BMSC-CM) in our study.

Microglia culture

Primary microglial cells were enriched in vitro using the shaking method described by Giulian and Baker [25]. Briefly, 2-day-old male SD rat were sacrificed and soaked in 75% ethanol for 1 minute. Cerebral hemispheres were dissected out following standard techniques and anatomical landmarks and then meninges were peeled off. The hippocampus, basal ganglion, and olfactory bulb were carefully removed with microsurgical instruments under a microscope, and the remaining cortical tissue was minced with a pair of microsurgical scissors. The shredded tissue was then incubated with 1 mL trypsin and 1 mL PBS for 15 min in a 37°C water bath with occasional swirling. After centrifuging at 300× g for 3 minutes, the cells were plated into 75 cm2 flasks which had been coated with poly-L-lysine. Mixed glial cells were cultured in DMEM/F-12 containing 10% FBS at 37°C in 5% CO2 in air and 95% humidity. The culture medium was replaced with 15 mL fresh growth medium after 24 hours. Subsequently, one-half of the volume of culture medium was replaced with an equal volume of fresh growth medium twice per week. The mixed glial cell cultures were incubated for 10–14 days. At the end of this period, stratification had been reached and the microglial cells in the upper layer could be harvested. Expression of the typical marker CD11b was assessed by cytofluorometric analysis.

Treatments

The microglial cells were mainly divided into four experimental groups:

1) Control group: cells were incubated in DMEM/F-12 containing 10% fetal bovine serum (FBS).

2) LPS-treated group: cells were incubated in DMEM/F-12 containing 10% FBS and 1 µg/mL lipopolysaccharide (LPS).

3) Conditioned medium (CM) group: cells were incubated in BMSC-conditioned medium (described above) containing 10% FBS.

4) CM+LPS group: cells were incubated in BMSC-conditioned medium containing 10% FBS and 1 µg/mL lipopolysaccharide.

Proliferation assays

Cell proliferation was measured at the indicated time-points using the Cell Counting Kit-8 assay (CCK-8, Dojindo, Japan). Briefly, after isolation from mixed glial culture, microglial cells were plated into 96-well plates at a density of 1×104 cells/well with 100 µL of complete culture medium. After adhesion for 24 hours, the medium was changed to DMEM/F-12 or conditioned medium with or without LPS (1 µg/mL) and incubated for 12, 24, 48 and 72 hours. At the end of each culture period, 10 µL CCK8 reagent was added to each well and incubated for another 4 hours, at the end of which the absorbance was measured at a wavelength of 450 nm. In order to investigate whether the inhibitory effect of BMSCs was associated with NO, S-methylisothiourea sulfate (inhibitor of iNOS, 1 mM) was added to some groups to inhibit the secretion of NO from BMSCs. The conditioned medium derived from these groups was regarded as conditioned medium containing reduced NO. All of the experiments above were repeated at least three times.

Cytokine and Chemokine Measurements

We used Bio-Plex Pro Assays to measure the cytokines, chemokines and growth factors secreted by microglial cells and bone marrow-derived mesenchymal stem cells. Briefly, 3 mL microglial cells were plated into 6-well plates at a density of 2×105 cells/mL. These cells were divided into four treatment groups and cultured under the conditions described above. After incubating at 37°C for 48 hours, the supernatant was collected and centrifuged to remove debris. TNF-α, IL-1β, IL-4, IL-6, IL-10, IL-17, INF-γ, RANTES, MCP-1, MIP-2 and VEGF were measured by Bio-Plex Pro Assays (Bio-Rad Laboratories, Hercules, CA) in accordance with the manufacturer's instructions. Data analysis was performed using Bio-Plex Manager software.

Phenotype analysis

We investigated whether BMSCs affect the expression of CD11b and CD68 by resting or activated microglia. After culturing the microglia in the four different treatment media for 48 hours, microglia in the four groups were digested with trypsin, washed three times with PBS, and kept at 4°C. Cells were then stained with antibodies against CD11b (FITC-labeled; BD, San Diego, CA) and CD68 (FITC-labeled; AbD Serotec, Oxford, UK). As a control, cells were stained with mouse IgG1 isotype-control antibodies. The changes in CD11b and CD68 were assessed by cytofluorometric analysis and the results were expressed as the percentage of positively stained cells relative to the total cell number.

Phagocytosis assays

We incubated microglia with fluorescence-labeled latex beads to study their phagocytic activity. Briefly, 500 µL microglial cells were plated into 24-well plates at a density of 2×105 cells/mL. Cells were cultured in DMEM/F-12 or conditioned medium with or without LPS (1 µg/mL) and incubated at 37°C in 5% CO2 in air and 95% humidity. After 24 hours, 5 µL fluorescence-labeled latex beads (L3030, Sigma) were added into each well and cultures were incubated for a further 4 hours. At the end of the incubation period the cells were fixed with 4% paraformaldehyde for 10 minutes, and then washed with PBS five times to remove serum and unbound beads. The cells were then stained with 4′,6-diamidino-2-phenylindole (DAPI) and observed under a fluorescence microscope to observe whether the microglia were able to phagocytose the beads. Phagocytic activity was illustrated by the number of beads phagocytosed by the cells.

Quantification of apoptosis by TUNEL assay

The TUNEL assay, which was used for the detection of apoptosis, was performed using an in situ cell death detection kit, POD (Roche, Indianapolis, IN) in accordance with the manufacturer's instructions. Freshly-isolated microglial cells were seeded at 500 µL/well into 48-well plates at a density of 1×105 cells/mL. Cells were incubated in DMEM/F-12 or conditioned medium with or without LPS (1 µg/mL) for 48 hours, following which cells were fixed with 4% paraformaldehyde for 20 minutes and permeabilized with 0.1% Triton X-100 for 10 minutes at room temperature. Subsequently, the cells were incubated with TUNEL reaction mixture (45 µL of label solution and 5 µL of enzyme solution) for 60 minutes at 37°C. Apoptotic nuclei, with green fluorescence, were observed under a fluorescence microscope at 400× magnification. The result was estimated as the percentage of TUNEL-positive cells among the total number of cells. The TUNEL reagent can also use streptavidin-horseradish peroxidase conjugate and diaminobenzidine (DAB) to detect apoptotic nuclei.

Annexin V/propidium iodide assay

Apoptosis was also evaluated using annexin V/propidium iodide (PI) staining followed by flow cytometry. After treating with different media for 48 hours, microglial cells collected from the four groups were centrifuged at 300× g for 5 minutes and washed twice with cold PBS. Then the cells were resuspended in binding buffer and incubated with propidium iodide (PI) and annexin V-FITC (BD Biosciences Pharmingen, San Diego, CA) for 15 minutes at room temperature. A total of at least 10,000 events were collected and analyzed by flow cytometry (BD).

Statistical analysis

All data are presented as mean ± SD. Comparisons between multiple groups were performed using one-way ANOVA followed by Student's unpaired t-test. A value of P<0.05 was considered statistically significant. All calculations were performed using the Statistical Package for the Social Sciences, version 13.0 (SPSS, Chicago, IL).

Results

BMSCs inhibit proliferation of microglia

We investigated whether BMSCs inhibit the proliferation of microglia, the innate immune cells of the CNS. The results of the CCK8 assays clearly show that proliferation of microglial cells was significantly increased in the LPS-stimulated group at the indicated time-points (LPS groups vs. control groups, P<0.001 at 24, 48 hours, and P<0.01 at 72 hours, Figure 1), while treatment with BMSC-CM significantly inhibited proliferation (CM groups vs. Control groups, P<0.001 at 24, 48 and 72 hours). The proliferation of cells treated with BMSC-CM after LPS stimulation decreased significantly compared with that of cells treated with LPS alone (CM+LPS group vs. LPS group, P<0.001 at 24, 48 and 72 hours). This phenomenon demonstrates that BMSCs inhibit the activity of activated (LPS-treated) microglia by secreting soluble factors. We further investigated whether the inhibitory effect of BMSCs was associated with NO by using S-methylisothiourea sulfate (an inhibitor of iNOS) to inhibit NO secretion, and found that cells cultured in this conditioned medium grew better than cells cultured in conditioned medium without the NO inhibitor (Figure 2).

Figure 1. BMSCs inhibit proliferation of microglial cells.

Figure 1

Open in a new tab

To determine whether BMSCs influence the growth of microglia, we used conditioned medium derived from BMSCs to culture microglia with or without LPS. The results show that LPS (1 µg/mL) promotes the proliferation of microglia (LPS groups vs. control groups, **P<0.01, and ***P<0.001), while BMSC-CM was effective in inhibiting the proliferation of microglia. The number of cells in the group treated with conditioned medium and LPS (1 µg/mL) decreased significantly compared with cells treated with LPS alone (CM+LPS group vs. LPS group, ###P<0.001).

Figure 2. Role of NO in the BMSC-mediated inhibition of microglial proliferation.

Figure 2

Open in a new tab

We cultured microglia in conditioned medium derived from BMSCs with or without inhibition of NO production. In the CM+SMT groups, microglia were incubated in conditioned medium derived from BMSCs in which NO production was inhibited by the NO inhibitor S-methylisothiourea sulfate (SMT, 1 mM). We found that cells cultured in CM after inhibition of NO production (CM+SMT groups) showed increased proliferation compared to cells cultured in CM without inhibition of NO production (CM groups). Bars represent means plus or minus SD obtained from six independent experiments. A P value of less than 0.05 (*), or less than 0.01 (**) was considered statistically significant.

BMSCs inhibit phagocytosis by microglia

We used fluorescence microscopy to observe the phagocytosis of latex beads by microglia. As shown in Figure 3, we found that red fluorescent latex beads were phagocytosed most by microglia stimulated with LPS. Meanwhile, phagocytosis by microglia treated with BMSC-CM was significantly inhibited compared with the control groups. Activated microglia cultured in BMSC-CM exhibited reduced phagocytic capacity compared to cells cultured in LPS alone.

Figure 3. BMSCs inhibit phagocytosis by microglial cells.

Figure 3

Open in a new tab

We tested the capacity of microglia to phagocytose fluorescent-labeled latex beads by observing them under a fluorescence microscope (magnification 400×). The microglial cells were incubated in DMEM/F-12 or conditioned medium with or without LPS (1 µg/mL) at 37°C in 5% CO2 in air and 95% humidity. The nuclei were counterstained with DAPI. Following incubation with LPS (1 µg/mL) for 4 hours, microglia clearly ingested more latex beads than untreated control groups, while the phagocytic activity of microglia in the conditioned medium (CM) treated-groups was significantly inhibited.

BMSCs inhibit cytokine and chemokine secretion by microglia

In addition to phagocytic activity, cytokine production is another important function of microglia. Therefore, in order to better characterize the inhibitory effect of BMSCs, we analyzed cytokine production by microglia cultured in BMSC-CM. Microglia have been shown to release many cytokines, chemokines, and free radicals under inflammatory conditions. After subjecting the cells to the different treatments used in our experiment, we collected the supernatants and analyzed cytokine levels using Bio-Plex Pro assays for TNF-α, IL-1β, IL-4, IL-6, IL-10, IL-17, INF-γ, RANTES, MCP-1, MIP-2 and VEGF. Our results show that in the presence of LPS, microglia secrete more pro-inflammatory cytokines such as TNF-α and IL-1β, and chemokines such as RANTES and MIP-2 than controls; however, BMSC-CM significantly inhibited secretion of these factors (Figure 4A). LPS-treated microglia also produced more anti-inflammatory cytokines such as IL-6 and IL-10, and chemokines such MCP-1 in comparison to the control groups (Figure 4B). We analyzed the differences between the CM-treated groups and the control groups, and found that the supernatant derived from CM-treated groups contained more IL-6, IL-10, MCP-1, and VEGF compared to control groups, indicating that BMSCs produce large quantities of these factors (Figure 4B). In contrast, virtually no IL-4, INF-γ, or IL-17 secretion was detected in the above four groups.

Figure 4. BMSCs inhibit cytokine and chemokine production by activated microglia.

Figure 4

Open in a new tab

We analyzed cytokine and chemokine production by microglia using Bio-Plex Pro assays. (A) LPS-treated microglia produce more TNF-α, IL-1β, RANTES and MIP-2 than control microglia, while treatment with conditioned medium significantly inhibited production of these factors. (B) Microglia in the LPS-treated groups produced more IL-6, IL-10 and MCP-1 compared to control groups. The supernatant derived from conditioned medium-treated groups contained more IL-6, IL-10, MCP-1 and VEGF compared to control groups. A P value of less than 0.05 (*), less than 0.01 (**), and less than 0.001 (***) was considered statistically significant.

BMSCs inhibit the LPS-induced expression of activated microglia receptors

To investigate whether BMSCs could affect the surface expression of resting or activated microglia, the microglial phenotype was assessed by cytofluorometric analysis. As shown in Figure 5, after culture in LPS for 48 hours, cells displayed increased expression of CD68, a marker of activated microglia, whereas CD11b was not significantly modified. The expression of CD68 was significantly lower in microglia cultured in BMSC-CM compared to microglia cultured in DMEM/F-12, however, no downregulation of CD11b was detected. In the LPS+CM groups, cells showed lower expression of CD68 compared with cells in the LPS-treated groups, which indicated that BMSCs inhibit the LPS-induced expression of activated microglia receptors.

Figure 5. BMSCs alter LPS–induced upregulation of CD68 on microglia.

Figure 5

Open in a new tab

Expression of CD11b and CD68 on microglia were assessed by cytofluorometric analysis. Cells were treated with DMEM/F-12 or conditioned medium with or without LPS and incubated for 48 hours. Red profiles represent expression of activating receptors; Blue profiles represent negative controls. Numbers indicate percentages of positive cells.

BMSCs mediate microglial apoptosis

We further investigated the effects of BMSC-CM on apoptosis of microglial cells using the TUNEL assay. Apoptotic cells exhibited pyknotic or split nuclei which could be identified by green fluorescent staining (Figure 6A). We were surprised to find that treatment of the microglial cells with LPS (1 µg/mL) for 48 h reduced the number of apoptotic cells from 4.5% to 1.8% of total cells (Figure 6B), a significant reduction compared to the control groups (P<0.05). However, treatment with conditioned medium increased the percentage of apoptotic cells to 11.2% (P<0.01). The percentage of apoptotic cells was also increased in the group treated with both LPS and BMSC-CM compared to the group treated with LPS alone (P<0.05). Apoptosis assessed by annexin V/propidium iodide (PI) assay showed the same trends as the TUNEL assay. As shown in Figure 7 (a representative experiment), after exposure to different media for 48 hours, the percentage of apoptotic cells in the LPS-treated groups was reduced compared with the control groups, while apoptotic cells in the CM groups increased dramatically compared with the control groups. BMSC-CM also induced apoptosis of activated microglial cells, as the CM+LPS groups contained more apoptotic cells than the LPS-treated groups. These results indicate that BMSC-CM not only exerts an inhibitory effect on proliferation of microglia, but also promotes their apoptosis.

Figure 6. BMSC-induced apoptosis of microglial cells.

Figure 6

Open in a new tab

We investigated the effects of conditioned medium on apoptosis of microglial cells by TUNEL assay. (A) Cells were observed under a fluorescence microscope (magnification 400×), or stained with DAB and observed under an optical microscope (magnification 400×). We found fewer apoptotic cells in the LPS-treated groups compared with the control groups, while apoptosis was increased in the groups cultured in BMSC-CM. (B) The percentage of apoptotic microglial cells among the total number of microglial cells in each group is shown. Bars represent means plus or minus SD obtained from eight random fields. *P<0.05, **P<0.01, compared with control groups.

Figure 7. Apoptosis assessed by annexin V/propidium iodide (PI) assay.

Figure 7

Open in a new tab

Annexin V/PI staining was performed to assess the apoptosis rate in microglia. After incubating in DMEM/F-12 or BMSC-CM with or without LPS (1 µg/mL) for 48 hours, microglia were harvested. Cells were then stained with annexin V-FITC and propidium iodide and analyzed by flow cytometry. The results are presented as density plots of propidium iodide vs. annexin V-FITC. Apoptotic cells have high annexin V-FITC and low propidium iodide staining (lower-right quadrant). Numbers on the graph represent the percentages of apoptotic cells in the different groups.

Discussion

In our present study, we provide evidence that BMSCs maintain the resting phenotype of microglia and inhibit their activity in vitro. Following incubation in BMSC-CM for different time periods, microglia treated with or without LPS showed reduced proliferation, weakened phagocytic capacity, and decreased expression of CD68. The results of Bio-Plex Pro assays show that production of TNF-α, IL-1β, RANTES, and MIP-2 by microglia increased significantly after LPS stimulation, but was significantly inhibited by BMSC-CM. BMSC-CM also inhibits the production of these factors by activated microglia which have been treated with LPS. We further analyzed differences between supernatant from CM-treated groups and control groups, and found that supernatant from the CM-treated groups contained more IL-6, IL-10, MCP-1, and VEGF compared to control groups. Finally, we measured levels of IL-4, IFN-γ, and IL-17 in the supernatant from the four groups, and found that virtually no IL-4, IFN-γ or IL-17 was produced by microglia treated with BMSC-CM. We further investigated possible reasons for the inhibitory effect of BMSCs, and concluded that BMSC-induced apoptosis and NO secretion could be relevant factors.

There have been previous reports of the immunosuppressive capacity of MSCs. For example, MSCs inhibit the proliferation of lymphocytes [26]–[29] and dendritic cells [30], [31]. In recent years, MSCs have been commonly used by researchers to attenuate immunological rejection and thus prolong graft survival [32]. Our study shows that BMSCs inhibit the proliferation of microglia, the resident immune cells of the CNS. Microglia are generally considered to be able to clear apoptotic cells without causing inflammation under normal conditions [33], but in the case of traumatic brain injury, or of some neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease, microglia are activated and can produce a lot of factors that are toxic to neighboring neurons. Since microglia are the most potent cells in initiating the CNS immune response, we believe that in order to identify the therapeutic mechanism of mesenchymal stem cells, it is important to figure out whether BMSCs influence the activity of microglia. In this study, we simulated possible influences of BMSCs in vitro by culturing microglia in BMSC-CM. We found that secretion of pro-inflammatory factors such as TNF-α and IL-1β, and chemokines such as MIP-2 and RANTES by activated microglia was significantly inhibited when they were cultured in BMSC-CM. TNF-α and IL-1β have been proven to be toxic to surrounding tissues and neurons, while MIP-2 and RANTES are factors which participate in recruitment of many immune cells. Thus the ability of BMSCs to inhibit the production of pro-inflammatory factors indicates that BMSCs could have negative effects on diseases mediated by activated microglia. Anti-inflammatory factors such as IL-6 and IL-10 are generally considered to be potent immunosuppressive cytokines which regulate growth and differentiation of a variety of immune cells [34]–[36]. Our study shows that production of large amounts of IL-6 and IL-10 may contribute to the inhibitory effect of BMSCs on proliferation of microglia. The secretion of VEGF shows that BMSCs are probably related to the production of vessels in the CNS, which could explain why BMSCs facilitate wound healing in many types of injury. In addition to the secretion of neurotoxic mediators, phagocytosis of neurons by microglia is also considered to be one of the causes of neurodegenerative disorders [8]. Under normal circumstances, dead and dying neurons are quickly removed through microglial phagocytosis. However, under inflammatory conditions, the phagocytosis range of microglia is expanded, which usually leads to death of healthy neurons. Our data provide evidence that BMSCs inhibit phagocytosis by activated microglia, indicating that BMSCs can reduce neuronal death to a certain extent. High levels of CD68 (ED-1) expression are associated with activated microglia, while low levels of CD68 expression are associated with quiescent ramified microglia [37]. We proved in our experiment that BMSC-CM show an inhibitory effect on the surface expression of CD68 receptors, indicating that BMSCs could reduce the number of activated microglia. We further investigated possible reasons for the inhibitory effect of BMSCs. TUNEL staining clearly showed that BMSCs promote apoptosis of resting as well as activated microglia. This phenomenon demonstrates that BMSCs not only inhibit the proliferation of microglia but also promote their apoptosis. In the LPS-stimulated groups, apoptosis was reduced, possibly because, during inflammatory activation, macrophages (microglia are considered to be the CNS equivalent of macrophages) can use significant amounts of glycolytically-generated ATP to maintain high mitochondrial membrane potential and prevent apoptosis [38]. Many soluble factors have been shown to be related to the inhibitory effect of mesenchymal stem cells, and two of these – prostaglandin E2 (PGE2) and indoleamine 2,3-dioxygenase (IDO) – are the most important factors which have been reported to participate in MSC-mediated suppression of many immune cells [26], [39]. Inhibition of PGE2 synthesis has been shown to boost production of TNF-α and IFN-γ by dendritic cells co-cultured with MSCs, while inhibition of PGE2 and IDO simultaneously completely restored NK-cell proliferation [40]. In this study, we investigated whether NO was involved in the inhibitory effect of BMSCs on microglia. Other studies have reported that NO is one of the inhibitory factors, although the mechanisms remain vague [41]. High concentrations of NO have been shown to suppress Signal Transducer and Activator of Transcription (STAT)5 phosphorylation in T cells and to induce immune cell apoptosis in vitro [42]. We used the NO inhibitor S-methylisothiourea sulfate (SMT) to block secretion of NO by BMSCs, and found that cells cultured in this conditioned medium (with a low NO content) showed increased proliferation compared to cells cultured in conditioned medium containing normal amounts of NO. This result indicates that the inhibitory effect exerted by BMSCs involves production of soluble factors, and that NO is involved.

In summary, our present study shows that BMSCs have the ability to maintain the resting phenotype of microglia or to control microglial activation. By producing several regulatory factors, BMSCs not only inhibit microglial proliferation, but also markedly suppress major microglial functions, such as phagocytic activity and cytokine production. In addition, BMSCs promote microglial apoptosis via their production of soluble factors. We also demonstrate that NO participates in the inhibitory effect of BMSCs. The immunosuppressive capability of BMSCs indicates that they can protect neurons and glia from damage by weakening the destructive cascade reaction caused by acute or chronic microglial activation. Our in vitro experiments reveal that BMSCs may be a promising therapeutic option for some CNS diseases associated with microglial activation. However, it is obvious that further in vivo studies in animal models will be needed to confirm the relevance of our in vitro findings.

Supporting Information

Figure S1

Phenotype of rat bone marrow-derived mesenchymal stem cells and microglia.

(TIF)

Click here for additional data file. (355.8KB, tif)

Funding Statement

This work was supported by grants from the funds for National Key Clinic Department, the Natural Science Fund of China (No. 81171179 and No. 81272439), the Guandong Natural Science Foundation (No. S2013020012754), the Funds for Key Sci-Tech Research Projects of Guangdong (No. 2008A030201019), and Funds for Key Sci-Tech Research Projects of Guangzhou (No. 09B52120112-2009J1-C418-2, No. 2008A1-E4011-6) to professor Xiaodan Jiang. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1. Nimmerjahn A, Kirchhoff F, Helmchen F (2005) Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308(5726): 1314–1318. [DOI] [PubMed] [Google Scholar]
  • 2. Walter L, Neumann H (2009) Role of microglia in neuronal degeneration and regeneration. Semin Immunopathol 31(4): 513–525. [DOI] [PubMed] [Google Scholar]
  • 3. Levesque S, Wilson B, Gregoria V, Thorpe LB, Dallas S, et al. (2010) Reactive microgliosis: extracellular µ-calpain and microglia-mediated dopaminergic neurotoxicity. Brain 133(3): 808–821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Raivich G (2005) Like cops on the beat: the active role of resting microglia. Trends Neurosci 28(11): 571–573. [DOI] [PubMed] [Google Scholar]
  • 5. Rock RB, Gekker G, Hu SX, Sheng WS, Cheeran M, et al. (2004) Role of microglia in central nervous system infections. Clin Microbiol Rev 17(4): 942–964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Burguillos MA, Deierborg T, Kavanagh E, Persson A, Hajji N, et al. (2011) Caspase signalling controls microglia activation and neurotoxicity. Nature 472(7343): 319–324. [DOI] [PubMed] [Google Scholar]
  • 7. Ghoshal A, Das S, Ghosh S, Mishra MK, Sharma V, et al. (2007) Proinflammatory mediators released by activated microglia induces neuronal death in Japanese encephalitis. Glia 55(5): 483–496. [DOI] [PubMed] [Google Scholar]
  • 8. Neher JJ, Neniskyte U, Zhao JW, Bal-Price A, Tolkovsky AM, et al. (2011) Inhibition of microglial phagocytosis is sufficient to prevent inflammatory neuronal death. J Immunol 186(8): 4973–4983. [DOI] [PubMed] [Google Scholar]
  • 9. Norden DM, Godbout GP (2012) Microglia of the aged brain: primed to be activated and resistant to regulation. Neuropathol Appl Neurobiol 39(1): 19–34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Saijo K, Crotti A, Glass CK (2012) Regulation of microglia activation and deactivation by nuclear receptors. Glia 61(1): 104–111. [DOI] [PubMed] [Google Scholar]
  • 11. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, et al. (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22(5): 1763–1771. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Blanc KL, Rasmusson I, Sundberg B, G?therstr?m C, Hassan M, et al. (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363(9419): 1439–1441. [DOI] [PubMed] [Google Scholar]
  • 13. Miyahara Y, Nagaya N, Kataoka M, Yanagawa B, Tanaka K, et al. (2006) Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat Med 12(4): 459–465. [DOI] [PubMed] [Google Scholar]
  • 14. Zanone MM, Favaro E, Miceli I, Grassi G, Camussi E, et al. (2010) Human mesenchymal stem cells modulate cellular immune response to islet antigen glutamic acid decarboxylase in type 1 diabetes. J Clin Endocrinol Metab 95(8): 3788–3797. [DOI] [PubMed] [Google Scholar]
  • 15. Shi YF, Su JJ, Roberts AI, Shou PS, Rabson AB, et al. (2012) How mesenchymal stem cells interact with tissue immune responses. Trends Immunol 33(3): 136–143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Uccelli A, Moretta L, Pistoia V (2008) Mesenchymal stem cells in health and disease. Nat Rev Immunol 8(9): 726–736. [DOI] [PubMed] [Google Scholar]
  • 17. Honma T, Honmou O, Iihoshi S, Harada K, Houkin K, et al. (2006) Intravenous infusion of immortalized human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat. Exp Neurol 199(1): 56–66. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Baker AH, Sica V, Work LM, Williams-Ignarro S, Nigris F, et al. (2007) Brain protection using autologous bone marrow cell, metalloproteinase inhibitors, and metabolic treatment in cerebral ischemia. Proc Natl Acad Sci U S A 104(9): 3597–3602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Hess DC, Hill WD, Carroll JE, Borlongan CV (2004) Do bone marrow cells generate neurons? Arch Neurol 61(4): 483–485. [DOI] [PubMed] [Google Scholar]
  • 20. Sanchez-Ramos J, Song S, Cardozo-Pelaez F, Hazzi C, Stedeford T, et al. (2000) Adult bone marrow stromal cells differentiate into neural cells in vitro. Exp Neurol 164(2): 247–256. [DOI] [PubMed] [Google Scholar]
  • 21. Sasaki M, Radtke C, Tan AM, Zhao P, Hamada H, et al. (2009) BDNF-hypersecreting human mesenchymal stem cells promote functional recovery, axonal sprouting, and protection of corticospinal neurons after spinal cord injury. J Neurosci 29(47): 14932–14941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Wilkins A, Kemp K, Ginty M, Hares K, Mallam E, et al. (2009) Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. Stem Cell Res 3(1): 63–70. [DOI] [PubMed] [Google Scholar]
  • 23. Jeong SR, Kwon MJ, Lee HG, Joe EH, Lee JH, et al. (2012) Hepatocyte growth factor reduces astrocytic scar formation and promotes axonal growth beyond glial scars after spinal cord injury. Exp Neurol 233(1): 312–322. [DOI] [PubMed] [Google Scholar]
  • 24. Koh SH, Baik W, Noh MY, Cho GW, Kim HY, et al. (2012) The functional deficiency of bone marrow mesenchymal stromal cells in ALS patients is proportional to disease progression rate. Exp Neurol 233(1): 472–480. [DOI] [PubMed] [Google Scholar]
  • 25. Giulian D, Baker TJ (1986) Characterization of ameboid microglia isolated from developing mammalian brain. J Neurosci 6(8): 2163–2178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Meisel R, Zibert A, Laryea M, G?bel U, D?ubener W, et al. (2004) Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103(12): 4619–4621. [DOI] [PubMed] [Google Scholar]
  • 27. Nicola DM, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, et al. (2002) Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99(10): 3838–3843. [DOI] [PubMed] [Google Scholar]
  • 28. Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, et al. (2005) Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 35(5): 1482–1490. [DOI] [PubMed] [Google Scholar]
  • 29. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M (2006) Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 24(1): 74–85. [DOI] [PubMed] [Google Scholar]
  • 30. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, et al. (2005) Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105(10): 4120–4126. [DOI] [PubMed] [Google Scholar]
  • 31. Liu WH, Liu JJ, Wu J, Zhang LL, Liu F, et al. (2013) Novel mechanism of inhibition of dendritic cells maturation by mesenchymal stem cells via interleukin-10 and the JAK1/STAT3 signaling pathway. PLoS One 8(1): e55487. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 32. Kuo YR, Chen CC, Goto S, Huang YT, Wang CT, et al. (2012) Immunomodulatory effects of bone marrow-derived mesenchymal stem cells in a swine hemi-facial allotransplantation model. PLoS One 7(4): e35459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Hughes MM, Fleld RH, Perry VH, Murray CL, Cunningham C (2010) Microglia in the degenerating brain are capable of phagocytosis of beads and of apoptotic cells, but do not efficiently remove PrPSc, even upon LPS stimulation. Glia 58(16): 2017–2030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Moore KW, Malefyt RW, Coffman RL, O'Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19: 683–765. [DOI] [PubMed] [Google Scholar]
  • 35. Pestka S, Krause CD, Sarkar D, Walter MR, Shi YF, et al. (2004) Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 22: 929–979. [DOI] [PubMed] [Google Scholar]
  • 36. Nauta AJ, Fibbe WE (2007) Immunomodulatory properties of mesenchymal stromal cells. Blood 110(10): 3499–3506. [DOI] [PubMed] [Google Scholar]
  • 37. Kingham PJ, Cuzner ML, Pocock JM (1999) Apoptotic pathways mobilized in microglia and neurons as a consequence of chromogranin A-induced microglial activation. J Neurochem 73(2): 538–547. [DOI] [PubMed] [Google Scholar]
  • 38. Garedew A, Henderson SO, Moncada S (2010) Activated macrophages utilize glycolytic ATP to maintain mitochondrial membrane potential and prevent apoptotic cell death. Cell Death Differ 17(10): 1540–1550. [DOI] [PubMed] [Google Scholar]
  • 39. Bouffi C, Bony C, Courties G, Jorgensen C, Noel D (2010) IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One 5(12): e14247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, et al. (2008) Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 111(3): 1327–1333. [DOI] [PubMed] [Google Scholar]
  • 41. Bogdan C (2001) Nitric oxide and the immune response. Nat Immunol 2(10): 907–916. [DOI] [PubMed] [Google Scholar]
  • 42. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, et al. (2007) Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 109(1): 228–234. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Figure S1

Phenotype of rat bone marrow-derived mesenchymal stem cells and microglia.

(TIF)

Click here for additional data file. (355.8KB, tif)

Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES